Toronto Dominion Bank Exelixis, Inc. Transaction History

Toronto Dominion Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Feb 14, 2024	SELL	$19.04 - $22.74 $17,878 - $21,352	-939 Reduced 0.97%	95,372 $2.08 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $17,878 - $21,352	-939 Reduced 0.97%	95,372 $2.08 Million
Q2 2023 Feb 14, 2024	BUY	$18.17 - $20.48 $1.75 Million - $1.97 Million	96,311 New	96,311 $1.84 Million
Q2 2023 Aug 10, 2023	BUY	$18.17 - $20.48 $1.75 Million - $1.97 Million	96,311 New	96,311 $1.84 Million

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

Stay updated on Toronto Dominion Bank with notifications on news.